Suzanne R. Hayman

TL;DR: Improved outcome of patients with myeloma in recent years is demonstrated, both in the relapsed setting as well as at diagnosis, both from time of diagnosis and the time of relapse.

TL;DR: It is demonstrated that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably, highlighting the impact of initial therapy with novel agents.

TL;DR: In this article, the authors developed a prognostic model based on 810 patients with newly diagnosed light chain (AL) amyloidosis, which was further examined in two other datasets: 303 patients undergoing stem-cell transplantation, and 103 patients enrolled onto different clinical trials.

TL;DR: The results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma were reported in this paper, where 34 patients achieved an objective response including 2 (6%) achieving complete response (CR) and 11 (32%) meeting criteria for both very good partial response and near complete response, resulting in an overall objective response rate of 91%.

TL;DR: This set of recommendations represents the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.